<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02115113</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001HIT34</org_study_id>
    <secondary_id>2013-004325-91</secondary_id>
    <nct_id>NCT02115113</nct_id>
  </id_info>
  <brief_title>REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy</brief_title>
  <acronym>REFLECT</acronym>
  <official_title>Multicenter, Prospective, Open-label, Controlled, Randomized, Parallel Groups Study to Evaluate the Renal Function of Adult Liver Transplant Recipients Treated With Two Everolimus-based Immunosuppressive Regimens (Tacrolimus Withdrawal vs. Minimization) Until 12 Months Post-transplant, With a 6-months Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is, starting from the Italian clinical practice in liver
      transplantation, to optimize the immunosuppressive therapy, considering specific patient
      characteristics as alcoholic cirrhosis, hepatitis C virus (HCV), hepatocellular carcinoma
      (HCC), and short/long-term implications. Then efficacy and safety of a calcineurin inhibitor
      (CNI)-withdrawal regimen will be evaluated in comparison with a CNI-minimization regimen.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function assessed by estimated glomerular filtartion rate (eGFR) using the MDRD-4 formula (Modification of Diet in Renal Disease, 4 variables)</measure>
    <time_frame>At 12 months post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite efficacy failure rate of treated biopsy proven acute rejection (tBPAR), Graft Loss (GL) or Death (D)</measure>
    <time_frame>At 12 months post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">415</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Group A (Tacrolimus Elimination Arm)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (Tacrolimus Minimization Arm)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
At 5 months after transplant, doses will be adjusted to achieve C-0h blood trough level target ranges 6-10 ng/mL.
Tacrolimus withdrawal should be completed by 6 months after transplant.</description>
    <arm_group_label>Group A (Tacrolimus Elimination Arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration. At 5 months after transplant, doses will continue to be adjusted to achieve C-0h blood trough level target ranges 3-8 ng/mL.</description>
    <arm_group_label>Group B (Tacrolimus Minimization Arm)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration. At 5 months after transplant, doses will continue to be adjusted to achieve C-0h blood trough level target ranges 3-5 ng/mL.</description>
    <arm_group_label>Group B (Tacrolimus Minimization Arm)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria at Baseline:

          -  Male and female liver transplant recipients who are ≥ 18 years of age, treated with a
             tacrolimus-based immunosuppressive regimen, who have received an induction therapy or
             i.v. steroids as per local clinical practice.

          -  Recipients of a full-size or technically modified liver allograft will be eligible at
             4 weeks (± 7 days) after liver transplantation.

          -  Allograft is functioning at an acceptable level by the time of Baseline as defined by
             the AST, ALT, total bilirubin levels ≤ 3 times ULN and INR &lt; 1.5 times ULN.

          -  Abbreviated MDRD-4 eGFR ≥ 30 mL/min/1.73m2. Serum creatinine results obtained within 5
             days prior to Baseline are acceptable.

        Inclusion criteria at Randomization:

          -  Effective tacrolimus minimization, confirmed by stable blood trough levels in the two
             months prior to randomization, i.e. verification of last two tacrolimus blood trough
             level ≤ 5 ng/mL in the two months prior to randomization. Investigators should make
             adjustments in tacrolimus dosing to continue to target trough levels ≤ 5 ng/mL prior
             to randomization.

          -  Abbreviated MDRD-4 eGFR ≥ 30 mL/min/1.73m2. Serum creatinine results obtained within 5
             days prior to Visit 5 are acceptable.

        Exclusion criteria at Baseline:

          -  Patients who are recipients of multiple solid organ transplants, (e.g., multivisceral
             or combined liver-kidney transplants), or have previously received an organ or tissue
             transplanted, or who received an AB0 incompatible transplant.

          -  Patients who experienced more than one episode of treated biopsy proven acute
             rejection (BANFF ≥ 3 or RAI ≥ 7) or one steroid-resistant acute rejection.

          -  Patients who require renal replacement therapy.

          -  Patients with a confirmed spot urine protein/creatinine ratio that indicates ≥1.0 g/24
             hrs of proteinuria.

          -  History of malignancy of any organ system within the past 5 years whether or not there
             is evidence of local recurrence or metastases, other than non-metastatic basal or
             squamous cell carcinoma of the skin or HCC.

        Exclusion criteria at Randomization:

          -  Patients who experienced more than two episodes of treated biopsy proven acute
             rejection (BANFF ≥ 3 or RAI ≥ 7) since transplantation or one steroid-resistant acute
             rejection during the run-in period.

          -  Patients with a confirmed spot urine protein/creatinine ratio that indicates ≥ 3.0
             g/24 hrs of proteinuria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cagliari</city>
        <state>CA</state>
        <zip>09134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2014</study_first_submitted>
  <study_first_submitted_qc>April 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver transplantation, everolimus, CNI-minimization, CNI-elimination, renal function</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 20, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>February 20, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

